We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience, read our Cookie Policy

Alnylam Files CTA to Initiate a Phase I Study for ALN-AT3

News   Nov 01, 2013

 
Alnylam Files CTA to Initiate a Phase I Study for ALN-AT3
 
 
 

RELATED ARTICLES

Peanut Allergy Treatment Ready for FDA Review

News

Study shows it is possible for some people with peanut allergy to protect themselves from accidental ingestion by building up their tolerance to peanut over time.

READ MORE

Drug Reduces Menstrual Bleeding for Women with Gynecologic Tumors

News

A new oral drug significantly reduced menstrual bleeding for women with the most common gynecologic tumors in the United States - benign tumors that disproportionately affect African-Americans, an international clinical trial found.

READ MORE


 

Like what you just read? You can find similar content on the communities below.

Drug Discovery

To personalize the content you see on Technology Networks homepage, Log In or Subscribe for Free

LOGIN SUBSCRIBE FOR FREE